Phase 4Terminated

Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)

An Open-Label, Randomized, Parallel-Group, Multicenter Study to Compare the Efficacy and Safety of "Switching" to Rosuvastatin 10 mg Daily Versus Atorvastatin 10 mg Daily With Ezetimibe 10 mg Daily Versus Doubling the Dose of Atorvastatin to 20 mg Daily in Subjects With Hypercholesterolemia and Atherosclerotic or Coronary Vascular Disease or Diabetes Mellitus Who Have Not Achieved Study Target LDL-C Goal While Dosing With Atorvastatin 10 mg Daily

Sponsor
Organon and Co (Industry)
Enrollment
87 enrolled
Conditions
Hypercholesterolemia; Atherosclerosis; Coronary Artery Disease
Interventions
Rosuvastatin; Ezetimibe + Atorvastatin; Double Atorvastatin
Ages
adults, older adults
Registry
NCT00651378

Full record on ClinicalTrials.gov

From the registry

This study assesses whether adding ezetimibe 10 mg/d to ongoing treatment with atorvastatin 10 mg/d is more effective than switching the subject to treatment with rosuvastatin 10 mg/d or doubling the dose of atorvastatin to 20 mg/d is more effective in achieving goal LDL-cholesterol of \<2.5 mmol/L. Treatment phase is 6 weeks.

Primary outcomes

  • Percent change in LDL-C level from baseline to the study endpoint.

History

  1. Last registry update

  2. Registered

  3. Primary completion

  4. Started